SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis
SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis
复制标题
SPARCL1，一种新的胃肠道恶性肿瘤预后预测因子：荟萃分析
DOI：
10.1159/000485584
复制
发表时间：
2017-01-01
影响因子：
--
通讯作者：
Ge, Weting
中科院分区：
文献类型：
--
作者：
Hu, Hanguang;Cai, Wen;Ge, Weting
背景/目的：富含半胱氨酸的酸性分泌蛋白1（SPARCL 1）在胃肠道恶性肿瘤中异常表达。然而，SPARCL 1表达与患者预后之间的相关性仍不清楚。因此，我们进行了一项荟萃分析，以研究SPARCL 1作为GI恶性肿瘤预后预测标志物的潜在价值。研究方法：对PubMed、Embase、EBSCO、CNKI和万方数据库进行系统检索，以查找研究SPARCL 1和临床病理学特征（包括患者病史）的研究。使用随机效应或固定效应模型计算并汇总来自个体研究的风险比（HR）和比值比（OR）。进行异质性和发表偏倚分析。结果：总结了8项研究的数据，共包括2，356例患者。SPARCL 1的表达提示预后较好（HR=0.57，95%CI：0.445-0.698，P=0.000），与胃肠道恶性肿瘤的临床病理特征相关，包括远处转移（OR=0.44，95% CI：0.23-0.85，P=0.014）、淋巴结转移（OR=0.56，95% CI：0.39-0.81，P=0.002）和肿瘤分化程度（OR=2.21，95% CI：1.82-2.69，P=0.000）。基于癌类型的亚组分析显示，SPARCL 1的表达对结直肠癌的淋巴结转移没有影响，对胃癌的肿瘤分化没有影响。Egger检验未发现发表偏倚（均P>0.05）。结论：SPARCL 1可能是一个新的胃肠道恶性肿瘤的预后预测因子。SPARCL 1的表达可影响胃肠道恶性肿瘤的临床病理特征。进一步的大规模研究对证实SPARCL 1的预后预测价值至关重要，需要更多基础实验研究来阐明其机制。(C)2017作者（s）由S. Karger AG，巴塞尔
Background/Aims: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is abnormally expressed in gastrointestinal (GI) malignancies. However, the correlation between SPARCL1 expression and the prognosis of patients remains unknown. Therefore, we performed a meta-analysis to investigate the potential value of SPARCL1 as a prognostic predictive marker for GI malignancies. Methods: The PubMed, Embase, EBSCO, CNKI, and Wanfang databases were systematically searched for studies examining SPARCL1 and clinicopathological features, including the prognoses of patients. Hazard ratios (HRs) and odds ratios (ORs) from individual studies were calculated and pooled using a random-effects or fix-effects model. Heterogeneity and publication bias analyses were performed. Results: Data from 8 studies, including a total of 2,356 patients, were summarized. The expression of SPARCL1 suggested a better prognosis (HR=0.57, 95% CI: 0.445-0.698, P=0.000) and was associated with clinicopathological features of GI malignancies, including distant metastasis (OR=0.44, 95% CI: 0.23-0.85, P=0.014), lymph node metastasis (OR=0.56, 95% CI: 0.39-0.81, P=0.002) and tumor differentiation (OR=2.21, 95% CI: 1.82-2.69, P=0.000). Subgroup analyses based on cancer type revealed that the expression of SPARCL1 had no effect on lymph node metastasis in colorectal cancer, and it did not influence tumor differentiation in gastric cancer. Egger's test showed no evidence of publication bias (all P>0.05). Conclusion: SPARCL1 could be a novel prognostic predictive factor for GI malignancies. The expression of SPARCL1 could influence the clinicopathological features of GI malignancies. Further large-scale studies are essential to confirm SPARCL1' s prognostic predictive value, and more fundamental experimental studies are needed to illustrate the mechanisms. (C) 2017 The Author(s) Published by S. Karger AG, Basel